Cipla Health’s Maxirich fortifies immunity boosting range


Launches Maxirich Vitamin C + Zinc Chewable Tablets and Maxirich Gold Supplement

Maxirich, the flagship health supplement brand of Cipla Health, has recently introduced two new products- Maxirich Vitamin C+ Zinc Chewable Tablets and Maxirich Gold Advanced Daily Supplement thereby extending the brand’s immunity building product offerings to consumers.

Maxirich Vitamin C+ Zinc chewable tablets have antioxidant properties that strengthen immune system and also help to reduce fatigue. They are available in tangy orange flavour making it appeasing to the taste buds. Furthermore, Maxirich Gold is made up of high purity grade Ginseng extract, along with the goodness of 10 Vitamins and 9 Minerals, which together act as a catalyst in reducing stress levels, boosting energy, building immunity, bolstering memory and concentration.

Commenting on the launch,  Shivam Puri, CEO, Cipla Health Ltd. said, “We at Cipla Health are constantly striving to offer the most effective healthcare products that will benefit our consumers in these trying times. Our flagship Maxirich brand has played an integral role in protecting consumers and helping them to build immunity through multivitamin supplements. Our continued efforts to ensure the well-being and overall health of our consumers have driven us to launch the Maxirich Vitamin C+ Zinc chewable tablets and Maxirich Gold which are important product extensions catering to the current requirements of the people.

Maxirich Vitamin C+ Zinc strip pack contains 15 chewable tablets priced at Rs 70, whereas Maxirich Gold pack containing 7 capsules is available at Rs 69. All Maxirich products including the Multivitamin supplements and Tulsi drops are available over the counter in medical stores pan India as well as online e-commerce platforms like, among others.

Read Previous

Nearly all Americans indulge in daily chocolate treat: Cargill survey

Read Next

Zeon Lifesciences launches plant-based immunity booster supplements

Leave a Reply